CLIVEMAUND.com STRONG BUY Rating - Aid and COVID-1
Post# of 155138
(Total Views: 1671)
Posted On: 06/21/2020 11:20:56 PM
CLIVEMAUND.com STRONG BUY Rating - Aid and COVID-19 stock on verge of starting another powerful upleg.
Cytodyn is a stock that is in an ongoing powerful bullmarket, which is not surprising considering the news coming out of the company. Dates for the commercial sale of their proprietary leronlimab drug for use against HIV and possibly for emergency use against COVID -19 are expected to be announced soon and also other news, and the stock is expected to uplist to the NYSE or NASDAQ.
Some of you may recall that we made a quick 53% gain in this stock in a week back in April when we took profits largely because it had become so overbought, and we resolved to stand aside and await developments. It is somewhat remarkable that we made that gain at a time when the stock was already in consolidation mode following a steep 2nd upwave in March as we can see on its latest 7 month chart.
Cytodyn is a stock that is in an ongoing powerful bullmarket, which is not surprising considering the news coming out of the company. Dates for the commercial sale of their proprietary leronlimab drug for use against HIV and possibly for emergency use against COVID -19 are expected to be announced soon and also other news, and the stock is expected to uplist to the NYSE or NASDAQ.
Some of you may recall that we made a quick 53% gain in this stock in a week back in April when we took profits largely because it had become so overbought, and we resolved to stand aside and await developments. It is somewhat remarkable that we made that gain at a time when the stock was already in consolidation mode following a steep 2nd upwave in March as we can see on its latest 7 month chart.
(6)
(0)